2021 Sustainability Report

Rob, living with Geographic Atrophy
Table of Contents

1  CEO LETTER

3  APELLIS AT A GLANCE

4  OUR PIPELINE

5  OUR APPROACH TO SUSTAINABILITY

6  PEOPLE
   Patients & Access to Medicine
   Diversity, Equity, and Inclusion (DEI)
   Recruitment, Engagement and Retention
   Training and Development

14 QUALITY AND SAFETY
   Drug Promotion Standards

17 ENVIRONMENT
   Emissions and Waste

18 INTEGRITY AND ETHICS

19 APPENDIX
   Sustainability Accounting Standards Board (SASB) Index
   Task Force on Climate-Related Financial Disclosures (TCFD) Index
A Message from the CEO

DEAR STAKEHOLDERS:

At Apellis, we strive to be known for our compassion, revolutionary science, and contributions to humankind around the world. We are built on the core belief that we can develop life-changing medicines to address a range of serious and debilitating diseases by controlling the complement cascade, which is a part of the body’s immune system. Our team is advancing courageous science, motivated by the opportunity to make a meaningful difference in the lives of patients and their families.

We also care fiercely about the greater good of society and believe corporate responsibility is foundational to achieving our vision. Therefore, as members of the broader communities in which we serve, we aim to operate with high ethical standards and ensure our decisions and actions are guided by our corporate values.

2021 was a transformative year for Apellis, as we received our first FDA approval, ushering in the first new class of complement medicine in 15 years. We transitioned from being an R&D-focused company to also being a commercial-stage company delivering the first and only targeted C3 therapy to patients. Under normal circumstances, these types of transitions require focus, dedication, and a tremendous amount of work. In the middle of a global pandemic, it also required agility and collaboration as we redefined how we worked. I am humbled by the dedication everyone at Apellis showed as we worked through these challenges, always putting patients first and placing sustainability at the forefront of what we do.

We are pleased to share details of our efforts in our inaugural Environmental, Social, and Governance (ESG) Report. We cover several policies and programs that are critical for our ESG initiatives, including how we recruit, develop, and retain employees; how we cultivate a diverse, equitable, and inclusive environment; how we implement quality practices focused on meeting patient needs and expectations; and how we help preserve and protect our environment.
A FEW HIGHLIGHTS INCLUDE:

• The establishment of ApellisAssist™, our patient support program, with the goal of ensuring that every person prescribed our medicine has access, regardless of the ability to pay, through one of the ApellisAssist financial assistance programs.

• The creation of a diversity, equity, and inclusion (DEI) program at Apellis aimed at developing and implementing a DEI strategy that aligns with our commitment to foster a sense of belonging and safety for all employees. We are also evaluating DEI-focused policies across our business.

• The launch of Project Apollo, an updated quality management system, focused on helping our teams efficiently drive compliance, product quality, innovation, and patient safety across the company.

Our executive team and Board of Directors support the continued growth of our sustainability efforts. We believe that by doing so, it will strengthen our ability to advance revolutionary science, deliver important new medicines to patients, and make a difference in people’s lives for many years to come. We recognize there is a lot of work to be done. I am excited by our initial progress and grateful to all Apellis employees as we seek to become a sustainable company and deliver on our vision.

Cedric Francois, M.D., Ph.D.  
CO-FOUNDER & CHIEF EXECUTIVE OFFICER/President

We aim to operate with high ethical standards and ensure our decisions and actions are guided by our corporate values.
Apellis at a Glance

WHO WE ARE — Leaders in Complement

At Apellis, we advance courageous science to deliver life-changing medicines across a broad range of serious diseases by controlling complement, a part of the immune system. Our world-class researchers have studied complement for over 20 years and in 2021, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy.

Controlling complement begins at C3, the central protein of the complement cascade. C3 is the only target in the complement cascade that addresses all three pathways that can initiate and drive disease. Targeting C3 may therefore offer comprehensive control of diseases with high unmet need that are driven by excessive complement activation. We are advancing a robust pipeline of targeted C3 programs across rare, retinal, and neurological diseases and aim to make a meaningful difference for patients around the world. We believe we are just scratching the surface of what may be possible.

OUR MISSION — To Boldly Deliver Revolutionary Therapies for People Living with Serious Diseases by Harnessing Complement

Founded in 2009 by a small group of entrepreneurs, including a physician and scientist who is our CEO, Apellis was established with the ambition to become the first company to develop a targeted C3 therapy for serious diseases driven by complement. Controlling C3 was viewed as scientifically difficult, if not impossible, by many, but the significant unmet needs of patients inspired our efforts and push us to continue to advance groundbreaking science for complement-driven diseases.

OUR VALUES — Bold at Our Core

Our company is formed by people who care, are fearless in the face of a challenge, love the work they do, are resourceful, and continually pursue the highest level of scientific integrity. These values guide every decision we make as we work toward our vision of being a compassionate organization known for its revolutionary science and contributions to humankind.
Our Pipeline

Building on our deep expertise in complement, we are developing potentially transformative complement-targeting therapies across a broad range of rare, retinal, and neurological diseases.

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DISEASE</th>
<th>PRECLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>LAUNCH</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMPAVELITM (systemic pegcetacoplan)*</td>
<td>PNH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Marketed in the US</td>
</tr>
<tr>
<td></td>
<td>IC-MPGN &amp; C3G</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ALS</td>
<td></td>
<td></td>
<td>Completed enrollment in March 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAD</td>
<td></td>
<td></td>
<td></td>
<td>Initiate Ph3 in 2H'22</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HSCT-TMA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>siRNA + EMPAVELI</td>
<td>Existing + new indications</td>
<td></td>
<td></td>
<td>IND in 1H'23</td>
<td></td>
</tr>
<tr>
<td>Intravitreal pegcetacoplan</td>
<td>GA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APL-2006</td>
<td>GA &amp; Wet AMD</td>
<td></td>
<td></td>
<td>IND in 1H'23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene therapies</td>
<td>Wet AMD, Intermediate AMD &amp; GA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APL-1030</td>
<td>Undisclosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain shuttle</td>
<td>Undisclosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene therapies</td>
<td>Undisclosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic pegcetacoplan</td>
<td>Control of host attack for gene therapies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral alternative pathway inhibitor</td>
<td>Mild C3G and other indications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene-edited therapies (Beam)</td>
<td>Undisclosed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Apellis and Sobi® have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, and Apellis has exclusive U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy.

Potential to be registrational.

Potential to be registrational.
Our Approach to Sustainability

At Apellis, we are committed to fostering a sustainable business that benefits patients, as well as our employees, investors, and communities. We strive to bring transformative medicines to patients, to provide an engaging and inclusive workplace for our employees, to minimize our impact on the environment, and to always demonstrate integrity in our actions.

Our sustainability policies and systems are reviewed and approved by our executive team and provide the framework in which we operate. We are guided in our decision-making and in our disclosures by our stakeholders and third-party frameworks including the Sustainability Accounting Standards Board (SASB) Biotechnology & Pharmaceuticals Standard and the Task Force on Climate-Related Financial Disclosures (TCFD).
At the heart of our company is the belief that revolutionary science, compassion, and humanity are intertwined. Our work to develop transformative therapies across a broad range of debilitating diseases is led by people who are nimble, fearless, and empowered to take risks and stretch to achieve the extraordinary. To succeed in our mission, we bring complementary strengths, different perspectives and lived experiences, and the space for every voice to be heard. In order to make the biggest impact, our goal is to be representative of the patient, caregiver, and community voice.

PATIENTS & ACCESS TO MEDICINE

Patients are at the forefront of what we do, and we are committed to ensuring that every eligible patient who wants our medicine will have access regardless of ability to pay. We strive to embed the experiences and opinions of the communities we serve into our business decisions, from discovery through to commercialization. Our goal is to design clinical trials, develop therapies, and apply resources that are representative of these communities. We deeply value the partnerships and collaborations with patients, healthcare providers, caregivers, payers, and patient advocacy groups, and we are committed to a continuous and transparent dialogue.

Our Head of Value, Access, and Policy and our Head of Patient Services are responsible for helping to ensure that our medicines are affordable and accessible. We determine pricing for our products based on several factors, most importantly the clinical profile of the medicine and the unmet need it addresses. Our Pricing Committee oversees our programs to provide access to medicine and reports regularly to our executive team, which reports to the Board of Directors for oversight. We also work closely with patients, healthcare providers, payers, and regulators as we establish strategies in support of disease awareness, diagnosis, health outcomes, treatment, and access.

We also have a dedicated team aligned to reimbursement- and insurance-related matters to ensure patient access and affordability. We launched a patient support program, ApellisAssist™, in connection with EMPAVELI® (pegcetacoplan)—our first product, which was approved by the U.S. Food and Drug Administration (FDA) in May 2021. To date, the ApellisAssist program has ensured that every person prescribed EMPAVELI has access to the medication, whether it is through insurance, one of the ApellisAssist financial assistance programs, or a combination thereof. Every person with PNH is unique and has their own needs when starting a new treatment. That is why the ApellisAssist program was created—to provide a comprehensive support system to meet those needs holistically. To quote a patient from our market research,

“Apellis is making sure that its patients are being cared for and that they’re feeling like all aspects of the drug, from manufacture to distribution, really has the patient’s best interest at heart.”
- EMPAVELI patient
The ApellisAssist Program

The ApellisAssist Program provides support to patients based on patients’ preferences and needs. We have learned what matters most to patients and created a curated support program.

FINANCIAL ASSISTANCE IS AVAILABLE TO ELIGIBLE PATIENTS

<table>
<thead>
<tr>
<th>Program</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apellis Co-Pay Program</td>
<td>For patients with commercial insurance to help cover co-pay and co-insurance costs.</td>
</tr>
<tr>
<td>Apellis Patient Assistance Program (PAP)</td>
<td>For patients with no insurance or limited coverage who meet financial eligibility criteria, program can provide EMPAVELI at no cost.</td>
</tr>
<tr>
<td>Apellis Quick Start Program</td>
<td>Helps with delays in patient insurance coverage. If a patient who is prescribed EMPAVELI experiences delays in coverage decisions or appeals, the program can provide a temporary supply in the interim.</td>
</tr>
<tr>
<td>Apellis Bridge Program</td>
<td>Helps with interruptions or changes in patient insurance coverage. If a patient is experiencing interruptions or changes in insurance coverage, they could be eligible to receive a temporary supply of EMPAVELI in the interim.</td>
</tr>
</tbody>
</table>

SMOOTH ONBOARDING AND PATIENT EDUCATION IS VITAL TO THE PATIENT EXPERIENCE

The ApellisAssist Program provides patients access to resources that can help integrate treatment into their lives.

CAREKIT BY APELLIS

Resources, including key infusion supplies, educational resources, and wellness items

HOME SUITE HOME

Helps patients organically integrate the process of self-infusion into their daily lives at home

MY INFUSION TRACKER

App developed with patients and caregivers in mind, so they can stay connected to and on top of their treatment with EMPAVELI.
SEPARATELY, we also have a dedicated patient marketing team to ensure that we are communicating the right information to patients at the right time in their journey. The goal is to empower patients with information so that they can have an informed conversation with their physicians. Apellis has created multiple resources to address this need. Below are a few of the resources we have created to help support patients throughout their journey with PNH:

- **PNH Peer2Peer Program:** This unique program allows people considering EMPAVELI treatment to connect directly with someone already on EMPAVELI and share their experiences with PNH diagnosis and treatment in a one-on-one conversation.

- **Administration Demonstration:** This program allows our team to educate a physician and their patient on the administration of EMPAVELI. Recognizing that many people might have questions about this process prior to starting therapy, this program allows the healthcare practitioner and the patient to have a discussion with someone on our team to address any of their questions as they consider whether or not EMPAVELI is right for them.

- **Ongoing Digital Educational Resources:** Through our websites (EMPAVELI.com and ThisIsPNH.com), our Facebook and Instagram pages, as well as our ongoing patient communications, we ensure that we are providing the most up-to-date and helpful information to the community, incorporating feedback and insights we hear from the PNH community.

**COMPASSIONATE USE AND EARLY ACCESS PROGRAMS**

We are committed to delivering innovative therapies to patients with serious diseases. This innovation means it takes time for our therapies to be approved for use in the market, as they need to be deemed safe and effective through the clinical trial and regulatory process. We understand that there are critically ill patients who do not have options for alternative therapies and are not eligible to participate in our clinical trials. In these circumstances, we will consider allowing access to the investigational therapy through our Compassionate Use (CU) or Early Access Program (EAP). CU is for an individual patient when no comparable or satisfactory alternative therapy options are available. An EAP is for a group of patients who have the same disease, which was evaluated in clinical trials and that we plan to submit to regulatory authorities in support of approval of the therapy.

Additionally, we are also committed to providing ongoing access to our therapies for those who participated in our clinical trials. Post-clinical-trial access might be available through different mechanisms, including but not limited to, long-term extension studies or other access programs.
Diversity, Equity, and Inclusion (DEI)

Apellis is proudly committed to being an equal-opportunity employer, where the opportunity to advance is made free of discrimination. We hire, develop, evaluate, and promote Apellis employees based on merit, suitability for the role, and potential development. Our DEI efforts are championed by our executive team and presented to and discussed with the Board of Directors quarterly by our Chief People Officer.

Our goal is to continue fostering an inclusive culture that supports a diverse, engaged, and thriving workforce. We truly believe that prioritizing efforts to create an environment where we all feel a sense of belonging and an ability to thrive is a critical component of our work. In 2021, a grassroots forum aimed at celebrating our unique qualities transformed into Belonging@Apellis, a DEI initiative comprising of two executive sponsors and a cross-functional team of employees across levels, functions, and locations across the globe. In collaboration with an external consultant, this team is charged with advancing our DEI efforts in a way that is impactful and sustainable as our business evolves, including developing and implementing a short- and long-term DEI strategy and program in alignment with our DEI vision. Our Head of the Rare Disease Program and Head of Corporate Development and Strategy currently have responsibility for developing and leading our DEI strategy and helping to ensure that all employees feel a strong connection with and commitment to our DEI efforts.

We actively integrate workforce diversity into several of our employee initiatives. In addition to working with our DEI consultant to further develop our diversity recruitment strategy, we also established a partnership with a diversity recruitment provider, enabling us to advertise positions across many DEI websites. We provide unconscious bias training for all employees, as well as regular training on our anti-discrimination and anti-harassment policies, which are parts of our Code of Business Conduct and Ethics (“Code”). Additionally, we closely monitor equity trends and utilize data from external compensation consultants to develop compensation packages and uphold pay equity.

This is only the beginning of our commitment to DEI, and we will continue to look for new ways to foster an inclusive culture and ensure DEI remains a core part of who we are.

“Since Apellis’ founding over a decade ago, diversity, equity, and inclusion (DEI) have been central to our values. Operating with dignity and respect is embedded in our culture. As we strive toward delivering revolutionary therapies to patients, we firmly believe that prioritizing efforts to foster an environment where all colleagues feel like they belong and can thrive is a critical component of our work.”

—Cedric Francois, M.D., Ph.D., Co-Founder & CEO
TO SUSTAIN OUR SUCCESS, WE EMBRACE DIVERSE PERSPECTIVES AND SEEK TO FOSTER EMPLOYEE ENGAGEMENT AND BELONGING (AS OF DECEMBER 31, 2021).

34% WOMEN IN SENIOR LEADERSHIP

6.8% ETHNIC DIVERSITY IN SENIOR LEADERSHIP

57% WOMEN IN THE WORKFORCE

25% ETHNIC DIVERSITY IN THE WORKFORCE
Recruitment, Engagement, and Retention

Our people are critical to our success, and we take pride in recruiting and retaining the best talent. We maintain a workforce plan on a three-year horizon, and we are in the process of developing a formal talent pipeline strategy for critical roles.

In 2021, we introduced a new corporate goal intended to measure our performance on strengthening engagement and the overall employee experience, focusing on key areas such as employee workload, operational support, and organization efficiency.

To monitor our progress and measure employee satisfaction, we conduct a formalized company-wide annual employee engagement survey, supplemented by pulse surveys. We believe in transparency and present results to all employees. We have taken many actions to improve the employee experience, including work prioritization, resource allocation, employee wellness, enhancements to employee benefits like additional mental health resources, changes to governance structure, and streamlining of decision-making. Finally, we actively monitor employee turnover at the executive level, with our Chief People Officer regularly reporting to and engaging with the Board of Directors on the subject. Our employee attrition has generally been significantly below market.

At Apellis, we are proud to offer industry-leading compensation and benefits packages to our employees. We cover 100% of our employees’ medical insurance costs. We also place an emphasis on our workforce’s mental well-being: we offer a specialized counseling app to promote mental health awareness for our employees and for their children. Our employees also enjoy generous parental leave and extended paid leave as part of the compensation and benefits package.

<table>
<thead>
<tr>
<th>BENEFITS AVAILABLE TO ALL EMPLOYEES INCLUDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Heart] Medical insurance with no premiums</td>
</tr>
<tr>
<td>[Disability Icon] Disability and life insurance with no premiums</td>
</tr>
<tr>
<td>[HSA Icon] Health Savings Account (HSA) contributions</td>
</tr>
<tr>
<td>[401k Icon] Retirement 401(k) match that immediately vests</td>
</tr>
<tr>
<td>[Employee Icon] Employee stock purchase plan (ESPP) to purchase shares at a discount</td>
</tr>
<tr>
<td>[Equity Icon] Equity awards for all employees</td>
</tr>
<tr>
<td>[Parental Icon] 10 weeks paid parental leave</td>
</tr>
<tr>
<td>[Life Coach Icon] 24/7 life coach support</td>
</tr>
<tr>
<td>[Healthcare Advocate Icon] Healthcare advocates service</td>
</tr>
</tbody>
</table>
Training and Development

At Apellis, we are committed to ensuring our people have the knowledge and skills to succeed and develop transformative medicines for patients. We created our first Leadership Development Program in 2021, and plan to launch our Matrix Leadership Development training program in 2022 for individuals working on our program teams. In 2022, we will launch broad-based training for all employees. We are proud to support advanced education and certifications for all full-time and part-time employees depending on their role. We also have formalized training programs for managerial, leadership, and patient- and customer-facing employees. We actively monitor training hours completed by our workforce on the topics of our Code, unconscious bias, and DEI. All our employees are eligible for quarterly Development Conversations, which focus on improving their current role performance and career planning for the future.

APELLIS LEADERSHIP DEVELOPMENT TOPICS

- Leadership styles
- Providing direction
- Coaching and feedback
- Development and feedback
- Effective decision making
- Influence management
- Change management
- Effective interviewing skills
- Behavioral interview
Apellis is committed to conducting medical and scientific research that demonstrates the highest levels of scientific integrity and inclusion. We have embarked on a purposeful journey to embed safety and quality in everything we do to help us deliver medicines of the highest quality to people who need them. We have tremendous respect for the patients who choose to participate in our clinical trials and are committed to ensuring their safety, health, and well-being. We also apply the highest ethical, scientific, and clinical standards in all our research endeavors.

Our approach to quality is to build it at the core of Apellis and throughout the product lifecycle, from our earliest research to our clinical, manufacturing, distribution, and pharmacovigilance work. All of us play an active and visible role in embedding quality into our culture through our actions and our decisions. We are dedicated to rigorous compliance with all laws and regulations regarding quality, safety, and performance requirements in every country where our products are available. Our Head of Quality has managerial responsibility for our product quality and safety. We recently launched Project Apollo, which is aimed at optimizing our teams’ performance to efficiently drive compliance, product quality, innovation, and patient safety across the company. This includes enhancements to our quality management system (QMS) designed to streamline our processes and training, encourage collaboration, and enable easy access to procedural documents.

“Our commitment to quality is essential to the lives and well-being of patients and to our success at Apellis. Quality is more than any one specific action, SOP, or department. It is a mindset that must be embedded at every working level and function, and it is a central consideration in our decision-making.”

— Cedric Francois, M.D., Ph.D., Co-Founder & CEO
With Project Apollo, we aim to have smoother workflows, sustain a new Process Champion governance model, implement a process-mapping tool, and establish role-based training. Our Project Apollo program consists of three pillars:

- Lifecycle Management: asset development through post-market management
- GxP Governance: cross-GxP good-practice quality management
- Operational Controls: clinical and commercial network and product management

We will provide mandatory Quality Manual training annually to all employees and contractors inclusive of annual pharmacovigilance training. We also offer additional training to employees based on their role. The ultimate purpose of our Quality Manual is to provide the following information:

- Quality-based operating principles
- Employee’s and manager’s quality responsibilities
- How our leaders commit to quality
- Summaries of our QMS framework and process
- Synopsis of each of the 3 pillars

We have developed standard operating procedures (SOPs) to ensure product quality and patient safety. We have set stringent product quality targets that we monitor for conformance and investigate any incidents: our product quality and safety target is always 100%.

We monitor performance through regular cross-functional senior leadership meetings.
on trends and data in product performance and safety. As part of our QMS, we have developed and maintain a dedicated Corrective and Preventive Action (CAPA) program, which states the incident investigation and corrective action procedures in the event of a product safety complaint or event. Further, we are committed to public reporting on product issues.

Drug Safety and Pharmacovigilance (DSPV) is also an integral part of our culture. The DSPV system ensures that we maintain compliance with applicable laws and regulations, as these govern, define, and regulate DSPV obligations and activities. All relevant pharmacovigilance-related activities are described in our SOPs, which are used to process, analyze, and report on our products.

We have a number of documented procedures governing our safety oversight, including:

- Project Management Plan (including KPIs)
- Governance Charter
- AERP: AE Reporting Plan for post-market and clinical trials

As an added measure to ensure patient safety, we perform ongoing monitoring of safety data for patients who receive our therapies and work with regulators to identify, mitigate, and communicate any potential risks.

All employees receive quality and safety training when they join Apellis and at least annually after that.

Drug Promotion Standards

Our ethical, scientific, and safety standards are of the highest measure, complying with all laws, guidelines, and industry codes at all times. All proposals for clinical trials and research grants go through an extensive review to confirm they meet our explicit internal standards as well as external laws and regulations. Ensuring the safety of clinical trial participants is our highest priority and we always obtain informed consent. The quality and safety of our products are paramount to our reputation, and we hold the same stringent standard for the promotion of our drugs.

Our Product Review Committee, composed of Legal, Medical Affairs, and Regulatory personnel, reviews and approves all external marketing documents. All employees also receive annual training from our Compliance team, and training on drug promotion standards is provided at our Plan of Action meetings.
At Apellis, we aim to maximize our impact on patients’ lives while minimizing the impact we have on the environment. We are committed to environmental stewardship by operating safely and efficiently and by minimizing our emissions and waste. Our environmental policies and programs ensure we comply with relevant regulations. As part of our environmental management program, we conduct monthly safety inspections of our laboratories. We hold semi-annual cleanout resets during which we close the laboratories and evaluate if the quality, aisle spacing, freezer inventory, and general perimeter guidelines are fully compliant with all applicable laws and regulations. These cleanouts also include an evaluation of the chemical inventory to minimize the on-site storage of unnecessary chemicals.

Environmental health is central to how we operate each day at Apellis. Each employee has their own recycling bin to minimize waste. Prior to the COVID-19 pandemic, we removed all single-use plastics in our offices (utensils, plates, cups, etc.) and asked that employees try to work only with food vendors that use recyclable materials. During the pandemic, we had to bring back individual use items for safety reasons, all of which are plant-based and biodegradable. Additionally, at all of our locations, we provide filtered water dispensers to minimize the use of plastic bottles. Since implementing these in our Waltham offices, we have saved nearly 125,000 bottles from being used, as of June 2022. Several of our locations also provide services to encourage the use of public transportation. This includes a shuttle to the offices, bike storage, and a carpool service in our Watertown, MA, location.

Apellis does not operate its own manufacturing facilities. Our research and development operations are located at a leased medical research facility that provides necessary environmental safety and compliance protocols. In 2021, we generated 6,030 lbs. of biological waste, which was treated safely with targeted incineration and disposed of in an environmentally conscious manner. All 170 lbs. of our hazardous waste generated was treated properly by a third-party vendor. Additionally, we generated 80 lbs. of non-hazardous waste. To further reduce our waste, we have launched a program to collect and recycle #5 polypropylene plastic.
We are committed to acting with integrity in all of our interactions with patients, suppliers, communities, and other stakeholders. We are guided by our Code and our compliance policies that apply to all employees, and we have Corporate Governance Guidelines that apply to our Board of Directors. Apellis maintains a robust business ethics program and a formalized Anti-Bribery and Anti-Corruption policy that is detailed in our Code.

We maintain an independent whistleblower hotline that offers anonymous, confidential, 24/7 reporting of any ethical concern. Contact details and information are provided via the Code, compliance training, and regular company communications. We have a process in place to assess all reports and route appropriately to our Human Resources, Compliance, or Legal department based on the type of issue raised. All reports are tracked and stored in our database and are investigated until resolved.

Our Supplier Code of Conduct provides guidance on business standards and advises us on making the right decision for patients, employees, and partners. It is a reminder that corporate integrity, responsible sourcing, and the safety and well-being of workers are of paramount importance to us. This code is our commitment to act with consistently high ethical standards and accept the same accountability for doing so as we expect of our trusted partners.

Roger, living with PNH
APPENDIX
## SASB Index

The following table provides data and information for Apellis utilizing the Sustainable Accounting Standards Board (SASB) Biotechnology and Pharmaceuticals standard. The data represents full-year 2021 performance.

<table>
<thead>
<tr>
<th>Categories</th>
<th>Accounting Metric</th>
<th>Code</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety of Clinical Trial Participants</strong></td>
<td>Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials</td>
<td>HC-BP-210a.1</td>
<td>We are committed to ensuring the safety, health, and well-being of our clinical trials participants and to having the highest ethical, scientific, and clinical standards in all of our research endeavors. All clinical trials follow Good Clinical Practice (GCP) and Good Pharmacovigilance Practice (GVP). For details, see the section Quality and Safety.</td>
</tr>
<tr>
<td></td>
<td>Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)</td>
<td>HC-BP-210a.2</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries</td>
<td>HC-BP-210a.3</td>
<td>Any material legal or regulatory issues would be disclosed in annual 10-K and quarterly 10-Qs.</td>
</tr>
<tr>
<td></td>
<td>Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index</td>
<td>HC-BP-240a.1</td>
<td>Patients are at the forefront of what we do, and we are committed to ensuring that every eligible patient who wants our medicine will have access regardless of ability to pay. For details, see the section Patients and Access to Medicine.</td>
</tr>
<tr>
<td></td>
<td>List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)</td>
<td>HC-BP-240a.2</td>
<td>Given the focus on rare disease, EMPAVELI does not qualify for the WHO List of Prequalified Medicinal Products.</td>
</tr>
<tr>
<td>Categories</td>
<td>Accounting Metric</td>
<td>Code</td>
<td>Information</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td><strong>Affordability &amp; Pricing</strong></td>
<td>Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period</td>
<td>HC-BP-240b.1</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year</td>
<td>HC-BP-240b.2</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year</td>
<td>HC-BP-240b.2</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database</td>
<td>HC-BP-250a.1</td>
<td>No products listed on MedWatch</td>
</tr>
<tr>
<td></td>
<td>Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System</td>
<td>HC-BP-250a.2</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Number of recalls issued, total units recalled</td>
<td>HC-BP-250a.3</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Total amount of product accepted for takeback, reuse, or disposal</td>
<td>HC-BP-250a.4</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type</td>
<td>HC-BP-250a.5</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting</td>
<td>HC-BP-260a.1</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products</td>
<td>HC-BP-260a.2</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products</td>
<td>HC-BP-260a.3</td>
<td>None</td>
</tr>
<tr>
<td>Categories</td>
<td>Accounting Metric</td>
<td>Code</td>
<td>Information</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>----------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ethical Marketing</td>
<td>Total amount of monetary losses as a result of legal proceedings associated with false marketing claims</td>
<td>HC-BP-270a.1</td>
<td>Any material legal or regulatory issues would be disclosed in annual 10-K and quarterly 10-Qs</td>
</tr>
<tr>
<td></td>
<td>Description of code of ethics governing promotion of off-label use of products</td>
<td>HC-BP-270a.2</td>
<td>For related information, see Drug Promotion Standards</td>
</tr>
<tr>
<td></td>
<td>Discussion of talent recruitment and retention efforts for scientists and research and development personnel</td>
<td>HC-BP-330a.1</td>
<td>Our people are critical to our success and we take pride in recruiting and retaining the best talent. For details, see Recruitment, Engagement and Retention</td>
</tr>
<tr>
<td></td>
<td>(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others</td>
<td>HC-BP-330a.2</td>
<td>Not reported Turnover rates (voluntary and involuntary) across Apellis are below the average industry trends. For details, see Recruitment, Engagement and Retention</td>
</tr>
<tr>
<td>Supply Chain Management</td>
<td>Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients</td>
<td>HC-BP-430a.1</td>
<td>Not reported</td>
</tr>
<tr>
<td>Business Ethics</td>
<td>Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery</td>
<td>HC-BP-510a.1</td>
<td>Any material legal or regulatory issues would be disclosed in annual 10-K and quarterly 10-Qs</td>
</tr>
<tr>
<td></td>
<td>Description of code of ethics governing interactions with health care professionals</td>
<td>HC-BP-510a.2</td>
<td>For details, see <a href="#">Code of Business Conduct and Ethics</a></td>
</tr>
<tr>
<td>Activity Metrics</td>
<td>Number of patients treated</td>
<td>HC-BP-000.A</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)</td>
<td>HC-BP-000.B</td>
<td>For details, see Our Pipeline</td>
</tr>
</tbody>
</table>
We are committed to providing transparency on our climate change risk management, governance, and performance. The Task Force on Climate-Related Financial Disclosures (TCFD) has developed voluntary, consistent climate-related financial risk disclosures for use by companies in providing information to stakeholders. A summary of our response to the TCFD-recommended disclosures is below.

**GOVERNANCE**

**Board oversight** — Our Board of Directors has ultimate oversight of climate change-related risks and is responsible for reviewing and providing guidance on the company’s climate change-related programs and policies as part of its wider sustainability oversight.

**Management oversight** — Our executive team recognizes the importance of discussing environmental risks and opportunities, including those related to climate change issues, and how to apply policies and strategies to address those in our business.

**STRATEGY**

We have identified climate change-related risks and opportunities that may impact our business over the short-, medium-, and long-term, which include the following:

**Physical Risks** — As a biopharmaceutical company, our products face few climate-related risks and they have little potential to have a significant financial impact on the business. However, we regularly assess how we might be influenced by a changing climate. We take seriously the potential for business disruption that could occur under extreme weather and natural disasters.

**Regulatory Risks** — We do not currently view climate-change as a significant business risk; however, it could pose regulatory risks such as through potential future carbon disclosure and compliance requirements, as well as reputational risks from not proactively addressing climate change issues. Possible carbon tax or regulatory incentives to encourage the use of renewables could affect energy costs. We do not expect this would have significant impact to our business and financial performance.

**Reputational Risks** — Failure to take sufficient action on climate-related impacts and risks could pose a reputational risk for our company. In response, we monitor industry-focused information sources on evolving risks, evolving litigation patterns involving the industry, and environmental concerns raised via shareholder proposals, and we seek input from our partners who support our environmental efforts.

**RISK MANAGEMENT**

Our executive team and Board of Directors are very keen on managing and mitigating various risks to our business and financial performance, including climate change and other environmental risks. Such risk management topics are reviewed and discussed among our leadership team across the entire organization.

**METRICS**

We are currently reviewing our disclosure of carbon emissions.
100 5th Avenue
Waltham, MA 02451,
USA

For all general inquiries,
please contact
info@apellis.com